Asklepion Pharmaceuticals

Asklepion Pharmaceuticals is a mission-driven biotech dedicated to addressing the unmet medical needs of children with rare and critical diseases. Founded in 2006, the company leverages partnerships and a focused pipeline to advance therapies from concept to commercialization. Key achievements include an FDA-approved product (Cholbam), Orphan Drug Designation for its lead candidate, a Special Protocol Assessment (SPA) with the FDA for its Phase 3 program, and recognition from the National Organization for Rare Disorders (NORD). Its strategic direction centers on advancing IV citrulline through late-stage trials for a severe pediatric complication.

Focuses on the development and repurposing of known biological molecules (e.g., L-citrulline, cholic acid) for novel, high-unmet-need indications in rare pediatric diseases, rather than a proprietary discovery platform.

For its lead program, Asklepion faces limited direct pharmaceutical competition, as there are no approved prophylactic drugs for CPB-induced acute lung injury. Competition is primarily from supportive standard of care. In the broader rare pediatric disease space, it competes with both large pharmaceutical orphan drug units and smaller biotech firms, differentiating itself through an exclusive pediatric focus and a regulatory-strategy-first approach.